GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ortin Laboratories Ltd (BOM:539287) » Definitions » EV-to-Revenue

Ortin Laboratories (BOM:539287) EV-to-Revenue : 6.02 (As of May. 25, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ortin Laboratories EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ortin Laboratories's enterprise value is ₹206.04 Mil. Ortin Laboratories's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₹34.23 Mil. Therefore, Ortin Laboratories's EV-to-Revenue for today is 6.02.

The historical rank and industry rank for Ortin Laboratories's EV-to-Revenue or its related term are showing as below:

BOM:539287' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.47   Med: 0.35   Max: 5.8
Current: 6.02

During the past 13 years, the highest EV-to-Revenue of Ortin Laboratories was 5.80. The lowest was -0.47. And the median was 0.35.

BOM:539287's EV-to-Revenue is ranked worse than
80.37% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs BOM:539287: 6.02

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Ortin Laboratories's stock price is ₹18.35. Ortin Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹4.03. Therefore, Ortin Laboratories's PS Ratio for today is 4.56.


Ortin Laboratories EV-to-Revenue Historical Data

The historical data trend for Ortin Laboratories's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ortin Laboratories EV-to-Revenue Chart

Ortin Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.15 4.06 2.92 3.38

Ortin Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.81 3.38 3.73 4.84 5.47

Competitive Comparison of Ortin Laboratories's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Laboratories's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ortin Laboratories's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ortin Laboratories's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ortin Laboratories's EV-to-Revenue falls into.



Ortin Laboratories EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Ortin Laboratories's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=206.038/34.232
=6.02

Ortin Laboratories's current Enterprise Value is ₹206.04 Mil.
Ortin Laboratories's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹34.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ortin Laboratories  (BOM:539287) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Ortin Laboratories's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=18.35/4.026
=4.56

Ortin Laboratories's share price for today is ₹18.35.
Ortin Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ortin Laboratories EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ortin Laboratories's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ortin Laboratories (BOM:539287) Business Description

Traded in Other Exchanges
Address
Street no. 3, D. No. 1-8-B4, Ground Floor,Block-4, F3 HIG, Baghlingampally, Hyderabad, TG, IND, 500 044
Ortin Laboratories Ltd is an India based engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its APIs Intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zudavudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others.It earns key revenue from domestic sales.

Ortin Laboratories (BOM:539287) Headlines

No Headlines